Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer

New England Journal of Medicine

Volumn 350, Issue 4, 2004, Pages 351-360

  Arriagada, Rodrigo ^a   Bergman, Bengt ^b   Dunant, Ariane ^c   Le Chevalier, Thierry ^c   Pignon, Jean Pierre ^c   Vansteenkiste, Johan ^d  

^a Instituto de Radiomedicina Santiago   (Chile)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; NAVELBINE; VINBLASTINE; VINDESINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BODY SURFACE; BONE MARROW APLASIA; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; FEMALE; FOLLOW UP; HEALTH CARE POLICY; HUMAN; HYPONATREMIA; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATHOGENESIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; VINBLASTINE; VINDESINE;

EID: 0346238665     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa031644     Document Type: Article

References (23)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. Lyons, France: International Agency for Research on Cancer, 2001 (software).
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
3. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998; 352:257-63.
4. Mountain CF. A new international staging system for lung cancer. Chest 1986;89: Suppl:225S-233S.
5. Pocock ST, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
6. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment Cancer 1981;47:207-14.
7. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343-6.
8. Haybittle JL. Repeated assessments of results in clinical trials of cancer treatment. Br J Radiol 1971;44:793-7.
9. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-220.
10. Wartelle M, Kramar A, Jan P, Kruger D. PIGAS: an interactive statistical database management system. In: Hammond R, MacCarthy JL, eds. Proceedings of the Second International Workshop on Statistical Database Management, Los Altos, California, September 27-29, 1983. Springfield, Va.: National Technical Information Service, Department of Commerce, 1983:124-32.
11. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
12. Rea D, Poole C, Gray R. Adjuvant tamoxifen: how long before we know how long? BMJ 1998;316:1518-9.
13. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr. Mortality from smoking in developed countries: 1950-2000: indirect estimates from national vital statistics. Oxford, England: Oxford University Press, 1994.
14. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003;95:1453-61.
15. Kato H, Tsuboi M, Ohta M, et al. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I (T1N0M0, T2N0M0) adenocarcinoma of the lung. Prog Proc Am Soc Clin Oncol 2003;22:621. abstract.
16. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med 2000;343:1217-22.
17. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small cell lung cancer. J Clin Oncol 2002;20:247-53.
18. Depierre A, Westeel V, Jacoulet P. Preoperative chemotherapy for non-small cell lung cancer. Cancer Treat Rev 2001;27:119-27.
19. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992;339:115, 71-85.
20. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and adjuvant ChemoTherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95:105-12.
21. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345:939-44.
22. Pignon J-P, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327:1618-24.
23. Aupérin A, Arriagada R, Pignon J-P, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999;341: 476-84.